作者
Hideho Okada, Pawel Kalinski, Ryo Ueda, Aki Hoji, Gary Kohanbash, Teresa E Donegan, Arlan H Mintz, Johnathan A Engh, David L Bartlett, Charles K Brown, Herbert Zeh, Matthew P Holtzman, Todd A Reinhart, Theresa L Whiteside, Lisa H Butterfield, Ronald L Hamilton, Douglas M Potter, Ian F Pollack, Andres M Salazar, Frank S Lieberman
发表日期
2011/1/1
期刊
Journal of clinical oncology
卷号
29
期号
3
页码范围
330
出版商
American Society of Clinical Oncology
简介
Purpose
A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly (I: C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+ patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100.
学术搜索中的文章
H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash… - Journal of clinical oncology, 2011